The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo

Archives of Pharmacal Research

Volumn 33, Issue 2, 2010, Pages 243-246

  Zheng, Jiao ^a   Chen, Bin ^a   Jiang, Bing ^a   Zeng, Ling ^a   Tang, Zhi Rong ^a   Fan, Lan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cytochrome P450 enzymes; In vivo; Induction; Inhibition; Isoflavone; Puerarin

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; PARAXANTHINE; PUERARIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG METABOLISM; ENZYME SUBSTRATE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; METABOLIC RATE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADULT; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; GENOTYPE; HUMANS; ISOFLAVONES; MALE; METOPROLOL; RANDOM ALLOCATION;

EID: 77949995285     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-0209-2     Document Type: Article

References (21)

1. S. Asimus D. Elsherbiny T. N. Hai B. Jansson N. V. Huong M. G. Petzold U. S. Simonsson M. Ashton 2007 Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects Fundam. Clin. Pharmacol. 21 307 316 10.1111/j.1472-8206.2007.00471.x 1:CAS:528:DC%2BD2sXmvVals7k%3D 17521300 (Pubitemid 46800472)
2. S. J. Billups T. Delate D. Dugan 2005 Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations Pharmacoepidemiol. Drug Saf. 18 253 257 10.1002/pds.1697
3. M. S. Faber A. Jetter U. Fuhr 2005 Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin. Pharmacol. Toxicol. 97 125 134 10.1111/j.1742-7843.2005.pto-973160.x 1:CAS:528:DC%2BD2MXhtVejsb3L 16128905 (Pubitemid 41291208)
4. L. Gao X. Ji J. Song P. Liu F. Yan W. Gong S. Dang Y. Luo 2009 Puerarin protects against ischemic brain injury in a rat model of transient focal ischemia Neurol. Res. 31 402 406 10.1179/174313209X444017 19508827
5. M. C. Guerra E. Speroni M. Broccoli M. Cangini P. Pasini A. Minghetti N. Crespi-Perellino M. Mirasoli G. Cantelli-Forti M. Paolini 2000 Comparison between Chinese medical herb Pueraria lobata crude extract and its main isoflavone puerarin Antioxidant properties and effects on rat liver CYP-catalysed drug metabolism Life Sci. 67 2997 3006 10.1016/S0024-3205(00) 00885-7 1:CAS:528:DC%2BD3cXotVWgsbg%3D 11133012
6. M. Kot W. A. Daniel 2008 Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat Pharmacol. Rep. 60 789 797 1:CAS:528:DC%2BD1MXmtFaisLY%3D 19211970
7. M. Kot J. Wójcikowski W. A. Daniel 2007 Caffeine metabolism during prolonged treatment of rats with antidepressant drugs Pharmacol. Rep. 59 727 733 1:CAS:528:DC%2BD1cXktVantbs%3D 18195463
8. L. Labbé C. Sirois S. Pilote M. Arseneault N. M. Robitaille J. Turgeon B. A. Hamelin 2000 Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates Pharmacogenetics 10 425 438 10.1097/00008571- 200007000-00006 10898112 (Pubitemid 30433576)
9. J. M. Liu L. Ma W. P. He 2002 Therapeutic effect of puerarin therapy on sudden deafness Di Yi Jun Yi Da Xue Xue Bao 22 1044 1045 12433647
10. Naveen Amrithraj Theophilus 2006 Adithan Chandrasekaran, Soya Sisy Sam, Nathalie Gerard, and Krishnamoorthy Rajagopalb, CYP2D6 genetic polymorphism in south indian populations Biol. Pharm. Bull. 29 1655 1658 10.1248/bpb.29.1655 1:STN:280:DC%2BD28vls1WnsQ%3D%3D 16880622 (Pubitemid 44166369)
11. D. S. Ou-Yang S. L. Huang H. G. Xie C. Y. Wang H. H. Zhou 1998 Use of caffeine as a probe for rapid determination of cytochrome P450 CYP1A2 activity in humans Acta Pharmacologica Sinica 19 44 46 1:CAS:528:DyaK1cXms12jtg%3D%3D 10375757
12. M. Paolini L. Pozzetti A. Sapone G. Cantelli-Forti 1998 Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases Life Sci. 62 571 582 10.1016/S0024-3205(97)01154-5 1:CAS:528:DyaK1cXitVaitg%3D%3D 9464470 (Pubitemid 28050076)
13. T. Rau H. Wuttke L. M. Michels U. Werner K. Bergmann M. Kreft M. F. Fromm T. Eschenhagen 2009 Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study Clin. Pharmacol. Ther. 85 269 272 10.1038/clpt.2008.218 1:CAS:528:DC%2BD1MXit1Oguro%3D 19037197
14. Y.-Q. Shun Y.-K. Hu 2005 Puerarin parenteral solution treat acute cerbral thrombosis Shang Dong Zhong Yi Za Zhi 24 469 470
15. Y.-P. Wu L. Wei 2000 Simutaneous determination of prapafenone and metoprolol in plasma by HPLC Chinese New Drugs Journal 9 99
16. T. Yagihashi M. Mizuno B. Chino Y. Sato K. Sakuma T. Takebayashi T. Takao K. Kosaki 2009 Effects of the CYP2D6 *10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia Hum. Psychopharmacol. 24 301 308 10.1002/hup.1025 1:CAS:528:DC%2BD1MXosFCksrc%3D 19387994
17. L.-P. Yan Y.-L. Zhuang S.-W. Chan S.-L. Chen G.-G. Shi 2009 Analysis of the mechanisms underlying the endothelium-dependent antivasoconstriction of puerarin in rat aorta Naunyn Schmiedebergs Arch. Pharmacol. 379 587 597 10.1007/s00210-008-0388-2 1:CAS:528:DC%2BD1MXksVOjtLg%3D 19190894
18. H. Yuan Z. Huang G. Yang H. Lv H. Sang Y. Yao 2008 Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol J. Int. Med. Res. 36 1354 1362 1:CAS:528:DC%2BD1MXhsValt74%3D 19094446
19. S.-Y. Zhang S.-L. Chen Y.-J. Shen D.-J. Yang X.-J. Liu A. C. Sun-Chi H.-X. Xu 2006 Puerarin induces angiogenesis in myocardium of rat with myocardial infarction Biol. Pharm. Bull. 29 945 950 10.1248/bpb.29.945 1:CAS:528:DC%2BD28Xmt1eht7k%3D 16651724
20. Zhou, H.-H., PHARMACOGENETICS Bei Jing: People's Military Medical Press, pp. 61-83, (2003).
21. S. F. Zhou 2008 Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4 Curr. Drug Metab. 9 310 322 10.2174/138920008784220664 1:CAS:528:DC%2BD1cXls1aitLY%3D 18473749